The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy

Cardiovascular Research

Volumn 79, Issue 3, 2008, Pages 481-491

  Jacques, Adam M ^a   Briceno, Natalia ^a   Messer, Andrew E ^a   Gallon, Clare E ^a   Jalilzadeh, Shapour ^b   Garcia, Edwin ^a   Kikonda Kanda, Gaelle ^a   Goddard, Jennifer ^b   Harding, Sian E ^a   Watkins, Hugh ^b   Esteban, M Tomé ^c   Tsang, Victor T ^c   McKenna, William J ^c   Marston, Steven B ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Contractile apparatus; Contractile function; Hypertrophic cardiomyopathy; Hypertrophy; Myectomy; Myosin; Protein phosphorylation

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ATENOLOL; CARDIAC MYOSIN; CLOPIDOGREL; DISOPYRAMIDE; FRUMIL; ISOPROTEIN; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 2; PHOSPHOPROTEIN; PROPRANOLOL DERIVATIVE; QUININE; TIMOLOL; VERAPAMIL;

ACTIN FILAMENT; ADULT; ARTICLE; CELL ISOLATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEART ATRIUM; HEART CONTRACTION; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE RELAXATION; HEART VENTRICLE; HEAVY CHAIN; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IN VITRO STUDY; LIGHT CHAIN; MALE; MUSCLE FIBER CONTRACTION; MUSCLE RESECTION; MUTATION; ORGAN DONOR; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SAMPLE; STAIN; STIMULUS; TWO DIMENSIONAL ELECTROPHORESIS; VELOCITY;

ADULT; CARDIAC MYOSINS; CARDIOMYOPATHY, HYPERTROPHIC; GENOTYPE; HEART FAILURE; HUMANS; MICROFILAMENTS; MIDDLE AGED; MUSCLE CONTRACTION; MUTATION; MYOCYTES, CARDIAC; MYOSIN HEAVY CHAINS; MYOSIN LIGHT CHAINS; PHENOTYPE; PHOSPHORYLATION; YOUNG ADULT;

EID: 48749118698     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn094     Document Type: Article

References (40)

1. Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 1999;44:20-36.
2. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C et al. Hypertrophic cardiomyopathy distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227-2232.
3. Van Driest SL, Jaeger MA, Ommen SR, Will ML, Gersh BJ, Tajik AJ et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:602-610.
4. Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ et al. Myosin-binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:1903-1910.
5. Knollmann BC, Potter JD. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. Trends Cardiovasc Med 2001;11:206-212.
6. Robinson PJR, Mirza M, Knott A, Abdulrazzak H, Marston S, Watkins H et al. Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy. J Biol Chem 2002;277:40710-40716.
7. 2+ regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type peptide. Circ Res 2000;86:1146-1152.
8. Palmiter KA, Tyska MJ, Haeberle JR, Alpert NR, Fananapazir L, Warshaw DM. R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Musc Res Cell Motil 2000;21:609-620.
9. James J, Zhang Y, Osonska H, Sanbe A, Klevitsky R, Hewett TE et al. Transgenic modelling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. Circ Res 2000;87:805-811.
10. Tardiff JC, Factor SM, Tompkins BD, Hewett TE, Palmer BM, Moore RL et al. A truncated troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest 1998;101:2800-2811.
11. Ashrafian H, Watkins H. Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies - therapeutics based on molecular phenotype. J Am Coll Cardiol 2007;49:1251-1264.
12. Kohler J, Winkler G, Schulte T, McKenna W, Brenner B, Kraft T. Mutation of the myosin converter domain alters cross-bridge elasticity. Proc Natl Acad Sci USA 2002;99:3557-3562.
13. Kirschner SE, Becker E, Antognozzi M, Kubis HP, Francino A, Navarro-Lopez F et al. Hypertrophic cardiomyopathy-related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells. Am J Physiol Heart Circ Physiol 2005;288:H1242- H1251.
14. Elliott PM, Gimeno JR, Tome MT, Shah J, Ward D, Thaman R et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-1941.
15. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy: a comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J 2002;23:1617-1624.
16. Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB et al. Operative treatment in hypertrophic subaortic stenosis: techniques and the results of pre- and postoperative assessments in 83 patients. Circulation 1975;52:88-102.
17. Messer AE, Jacques AM, Marston SB. Troponin phosphorylation and regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure. J Mol Cell Cardiol 2007;42:247-259.
18. 2+: the thin filament is switched as a single cooperative unit. J Biol Chem 1995;270:7836-7841.
19. Morano I, Hadicke K, Haase H, Bohm M, Erdmann E, Schaub MC. Changes in essential myosin light chain isoform expression provide a molecular basis for isometric force regulation in the failing human heart. J Mol Cell Cardiol 1997;29:1177-1187.
20. Steinberg TH, Agnew BJ, Gee KR, Leung WY, Goodman T, Schulenberg B et al. Global quantitative phosphoprotein analysis using multiplexed proteomics technology. Proteomics 2003;3:1128-1144.
21. Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 1995;92:2540-2549.
22. 2+ sensitivity. J Mol Cell Cardiol 2002;34:469-482.
23. 2+-dependant effects on actin-tropomyosin filament motility. Biochem J 1997;327:335-340.
24. Malmqvist UP, Aronshtam A, Lowey S. Cardiac myosin isoforms from different species have unique enzymatic and mechanical properties. Biochemistry 2004;43:15058-15065.
25. Kron SJ, Toyoshima YY, Uyeda TQP, Spudich JA. Assays for actin sliding movement over myosin coated surfaces. Methods Enzymol 1991;196:399-416.
26. Marston S. Random walks with thin filaments: application of in vitro motility assay to the study of actomyosin regulation. J Musc Res Cell Motil 2003;24:149-156.
27. Morano M, Zacharzowski U, Maier M, Lange PE, Alexi-Meskishvili V, Haase H et al. Regulation of human heart contractility by essential myosin light chain isoforms. J Clin Invest 1996;98:467-473.
28. 2+ sensitivity of force is enhanced in failing human hearts. Cardiovas Res 2003;57:505-514.
29. Gray R, Jacques A, Peters N, McKenna W, Walker J, McIntyre H et al. Electromechanical properties of isolated myocardium from patients with hypertrophic obstructive cardiomyopathy (HOCM). Circulation 2005;112(17 Supp 15):U149.
30. McIntyre H, Fry CH. Abnormal action potential conduction in isolated human hypertrophied left ventricular myocardium. J Cardiovasc Electrophysiol 1997;8:887-894.
31. 2+ sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res 2003;57:37-47.
32. Gallon CE, Messer AE, Copeland O, Jacques A, Tsang V, McKenna WJ et al. Post-translational modification of TnT, TnI, MyBP-C and MLC-2 in HOCM human heart muscle. J Muscle Res Cell Motil 2007, doi:10.1007/S10974-008- 9127-Z abstract#3:9.
33. El-Armouche A, Pohlmann L, Schlossarek S, Starbatty J, Yeh YH, Nattel S et al. Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. J Mol Cell Cardiol 2007;43:223-229.
34. Jacques A, Messer A, Tsang V, McKenna W, Marston S. Evidence for reduced troponin I phosphorylation and altered troponin function in patients with hypertrophic obstructive cardiomyopathy. J Mol Cell Cardiol 2006;40:939.
35. Palmer BM. Thick filament proteins and performance in human heart failure. Heart Fail Rev 2005;10:187-197.
36. Noguchi T, Camp P Jr, Alix SL, Gorga JA, Begin KJ, Leavitt BJ et al. Myosin from failing and non-failing human ventricles exhibit similar contractile properties. J Mol Cell Cardiol 2003;35:91-97.
37. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007;93:903-907.
38. Coirault C, Guellich A, Barbry T, Samuel JL, Riou B, Lecarpentier Y. Oxidative stress of myosin contributes to skeletal muscle dysfunction in rats with chronic heart failure. Am J Physiol Heart Circ Physiol 2006;292:H1009-H1017.
39. 2 on airway smooth muscle. J Biol Chem 2007;282:4336-4344.
40. Yamazaki T, Suzuki J, Shimamoto R, Tsuji T, Ohmoto Y, Toyo-Oka T et al. Focalized contractile impairment at hypertrophied myocardium proven in consideration of wall stress in patients with hypertrophic cardiomyopathy. Int Heart J 2006;47:247-258.